Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas

References

• Dunleavy K, Gross TG. Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective. Blood. 2018;132:369–375.
   PubMed Web of Science ®Google Scholar
• Caimi PF, Hill BT, Hsi ED, et al. Clinical approach to diffuse large B cell lymphoma. Blood Rev. 2016;30:477–491.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24:561–576.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignantlymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-celllymphoma. Ann Oncol. 2013;24:857–877.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Grouped'Etude des Lymphomes de l'Adulte. JCO. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA A Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:110–112.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. JCO. 2014;32:3490–3496.
   PubMed Web of Science ®Google Scholar
• Hou Y, Wang HQ, Ba Y. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma. Med Oncol. 2012;29:2409–2416.
   PubMed Web of Science ®Google Scholar
• Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP regimen in relapsed and/or refractory Hodgkin lymphoma: a comparison study. Int J Hematol Oncol Stem Cell Res. 2015;9:10–14.
   PubMedGoogle Scholar
• Schirmbeck NG, Mey UJ, Olivieri A, et al. Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Invest. 2016;34:361–372.
   PubMed Web of Science ®Google Scholar
• Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77:1103–1124.
   PubMed Web of Science ®Google Scholar
• Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334:115–124.
   PubMed Web of Science ®Google Scholar
• Peres LA, da Cunha AD Jr. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol. 2013;35:332–340.
   PubMedGoogle Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;0:364–378.
   Web of Science ®Google Scholar
• Lisenko K, McClanahan F, Schoning T, et al. Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma. BMC Cancer. 2016;16:267.
   PubMed Web of Science ®Google Scholar
• Tixier F, Ranchon F, Iltis A, et al. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematol Oncol. 2017;35:584–590.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Johnston PB, LaPlant BR, et al. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017;92:1004–1010.
   PubMed Web of Science ®Google Scholar
• Lacout C D, Vries M, Seegers-Thepot V, et al. R-DHA-oxaliplatin versus R-DHA-cisplatin regimen in B-Cell Nhl's treatment: a eight years retrospective study. Blood. 2015;126:3959.
   Web of Science ®Google Scholar
• Eloit M, Iltis A, Thieblemont C, et al. Substitution of cisplatin for carboplatin or oxaliplatin in the DHAP regimen is associated with improved survival in relapsed/refractory non-Hodgkin’s lymphoma. 23th Annual Congress of the European Hematology Association; 2018 Jun 14–17, Stockholm, Sweden.
   Google Scholar
• Clavio M, Garrone A, Pierri I, et al. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. Oncol Rep. 2005;14:933–940.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Fabbri A, Puccini B, et al. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer. 2010;116:4573–4579.
   PubMed Web of Science ®Google Scholar
• Delgado J, Pereira A, Villamor N, et al. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99:1410–1420.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182:633–643.
   PubMed Web of Science ®Google Scholar
• Lisenko K, Cremer M, Schwarzbich MA, et al. Efficient stem cell collection after modified cisplatin-based mobilization chemotherapy in patients with diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2016;22:1397–1402.
   PubMed Web of Science ®Google Scholar
• Gini G, Bocci C, Sampaolo M, et al. A combination of lenalidomide and rituximab (ReRi) as salvage therapy in elderly patients affected by diffuse large B cells (DLBCL) lymphoma relapsed and refractory. Blood. 2015;126:5109.
   Google Scholar
• Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902–1909.
   PubMed Web of Science ®Google Scholar
• Chiappella A, Santambrogio E, Castellino A, et al. Integrating noveldrugs to chemoimmunotherapy in diffuse large B-celllymphoma. Expert Rev Hematol. 2017;10:697–705.
   PubMed Web of Science ®Google Scholar